Archive: August 2023
Feature Article
Acral Melanoma: Clinical Advances and Hope for the Future
Abstract: Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma […]
Feature Article
Neoadjuvant Immunotherapy in Resectable Non–Small Cell Lung Cancer
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients […]
Letter From the Editor
Letter From the Editor: Dog Traits
Mojo, our family dog, passed away last month. Losing her made me realize what a valuable emotional support she had been for our family. As our […]
LLM
Recent Approval of Pirtobrutinib for Mantle Cell Lymphoma
H&O What is pirtobrutinib and how does it work? JC Pirtobrutinib (Jaypirca, Lilly) is a recently approved therapy for patients with relapsed or refractory mantle cell […]
Prostate Cancer In Focus
More Highlights in Prostate Cancer From the 2023 American Society of Clinical Oncology Annual Meeting
June 2-6, 2023 • Chicago, Illinois and Virtual Last month, Clinical Advances in Hematology & Oncology highlighted the PEACE-1 trial, the TALAPRO-2 study, and research on […]
Lung Cancer in Focus
Updates in Small Cell Lung Cancer
H&O How common is small cell lung cancer (SCLC), and who is at risk? JS Lung cancer is the second most common cancer type in men […]
Melanoma in Focus
Adjuvant Therapy in High-Risk, Node-Negative Melanoma
H&O Which patients with high-risk, node-negative melanoma should receive adjuvant therapy? MR First, it is important to define what is meant by “high-risk,” or what the […]
Advances in Drug Development
Novel Sources of Funding for Clinical Trials in Oncology
H&O What are the traditional sources of funding for clinical trials in oncology, and how have they evolved over time? GS Traditional sources of funding for […]
CLL
Management of Richter Transformation
H&O How often does chronic lymphocytic leukemia (CLL) transform into aggressive lymphoma? MD Transformation of CLL into aggressive lymphoma, known as Richter transformation (RT), is relatively […]